---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000056"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:04:21.572558+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio CFIUS review for asset sale to uBrigene enters investigation phase; decision by Feb 12, 2024

## Summary
- CFIUS began a 45-day investigation after the initial review period expired on Dec 28, 2023 without conclusion.
- CFIUS must complete its investigation no later than February 12, 2024.
- Transaction involves sale of Mustang's Worcester cell processing facility and assets to uBrigene, a Chinese CDMO.
- CFIUS clearance was not a condition to closing the transaction.
- The parties previously withdrew and re-filed their CFIUS notice on Nov 13, 2023 to allow more review time.

## SEC filing metadata
- accession: 0001558370-24-000056
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000155837024000056/0001558370-24-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000155837024000056/tmb-20231228x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000056
- JSON: https://secwatch.observer/filing/0001558370-24-000056.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.